Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 62 articles:
HTML format
Text format



Single Articles


    May 2018
  1. CAI H, Cho EA, Li Y, Sockler J, et al
    Melanoma protective antitumor immunity activated by catalytic DNA.
    Oncogene. 2018 May 29. pii: 10.1038/s41388-018-0306.
    PubMed     Text format     Abstract available


  2. XIAO P, Guo Y, Zhang H, Zhang X, et al
    Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-gamma production in tumor microenvironment.
    Oncogene. 2018 May 24. pii: 10.1038/s41388-018-0337.
    PubMed     Text format     Abstract available


  3. ZHU B, Tang L, Chen S, Yin C, et al
    Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy.
    Oncogene. 2018 May 22. pii: 10.1038/s41388-018-0314.
    PubMed     Text format     Abstract available


    April 2018
  4. ZHANG YY, Tabataba H, Liu XY, Wang JY, et al
    ACTN4 regulates the stability of RIPK1 in melanoma.
    Oncogene. 2018 Apr 30. pii: 10.1038/s41388-018-0260.
    PubMed     Text format     Abstract available


  5. REYES-URIBE P, Adrianzen-Ruesta MP, Deng Z, Echevarria-Vargas I, et al
    Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.
    Oncogene. 2018 Apr 26. pii: 10.1038/s41388-018-0247.
    PubMed     Text format     Abstract available


    March 2018
  6. ZUO Q, Liu J, Huang L, Qin Y, et al
    AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.
    Oncogene. 2018 Mar 19. pii: 10.1038/s41388-018-0205.
    PubMed     Text format     Abstract available


  7. MISKOLCZI Z, Smith MP, Rowling EJ, Ferguson J, et al
    Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.
    Oncogene. 2018 Mar 16. pii: 10.1038/s41388-018-0209.
    PubMed     Text format     Abstract available


  8. LI K, Zhang TT, Wang F, Cui B, et al
    Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression.
    Oncogene. 2018 Mar 9. pii: 10.1038/s41388-018-0172.
    PubMed     Text format     Abstract available


    February 2018
  9. TUSA I, Gagliardi S, Tubita A, Pandolfi S, et al
    ERK5 is activated by oncogenic BRAF and promotes melanoma growth.
    Oncogene. 2018 Feb 27. pii: 10.1038/s41388-018-0164.
    PubMed     Text format     Abstract available


  10. YU Y, Dai M, Lu A, Yu E, et al
    PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.
    Oncogene. 2018 Feb 2. pii: 10.1038/s41388-017-0061.
    PubMed     Text format     Abstract available


    October 2017
  11. ARAIZA-OLIVERA D, Feng Y, Semenova G, Prudnikova TY, et al
    Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  12. DIETRICH P, Kuphal S, Spruss T, Hellerbrand C, et al
    Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  13. GELATO KA, Schockel L, Klingbeil O, Ruckert T, et al
    Super-enhancers define a proliferative PGC-1alpha-expressing melanoma subgroup sensitive to BET inhibition.
    Oncogene. 2017 Oct 9. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    September 2017
  14. KIM KJ, Kwon SH, Yun JH, Jeong HS, et al
    STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression.
    Oncogene. 2017;36:5445-5459.
    PubMed     Text format     Abstract available


  15. KUO TF, Chen TY, Jiang ST, Chen KW, et al
    Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway.
    Oncogene. 2017;36:5484-5496.
    PubMed     Text format     Abstract available


  16. PEREGO M, Maurer M, Wang JX, Shaffer S, et al
    A slow-cycling subpopulation of melanoma cells with highly invasive properties.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  17. MAURUS K, Hufnagel A, Geiger F, Graf S, et al
    The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
    Oncogene. 2017;36:5110-5121.
    PubMed     Text format     Abstract available


    August 2017
  18. CHEN XW, Yu TJ, Zhang J, Li Y, et al
    CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis.
    Oncogene. 2017;36:5045-5057.
    PubMed     Text format     Abstract available


  19. LECLERC J, Ballotti R, Bertolotto C
    Pathways from senescence to melanoma: focus on MITF sumoylation.
    Oncogene. 2017 Aug 21. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    July 2017
  20. ZHANG W, Ding Y, Zhang C, Lu Q, et al
    Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor.
    Oncogene. 2017;36:4277-4287.
    PubMed     Text format     Abstract available


  21. HUANG L, Wang Z, Liu C, Xu C, et al
    CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner.
    Oncogene. 2017;36:4081-4086.
    PubMed     Text format     Abstract available


    June 2017
  22. LI Y, Zhou T, Wang Y, Ning C, et al
    The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation.
    Oncogene. 2017;36:3760-3771.
    PubMed     Text format     Abstract available


  23. AGAESSE G, Barbollat-Boutrand L, Sulpice E, Bhajun R, et al
    A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  24. DAMSKY WE, Bosenberg M
    Melanocytic nevi and melanoma: unraveling a complex relationship.
    Oncogene. 2017 Jun 12. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  25. PEREZ-ALEA M, McGrail K, Sanchez-Redondo S, Ferrer B, et al
    ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    May 2017
  26. GIEBELER N, Schonefuss A, Landsberg J, Tuting T, et al
    Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis.
    Oncogene. 2017 May 29. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    April 2017
  27. MOTZIK A, Amir E, Erlich T, Wang J, et al
    Post-translational modification of HINT1 mediates activation of MITF transcriptional activity in human melanoma cells.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  28. JAIN A, Tripathi R, Turpin CP, Wang C, et al
    Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  29. SCHAEFER SM, Segalada C, Cheng PF, Bonalli M, et al
    Sox2 is dispensable for primary melanoma and metastasis formation.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  30. CESARINI V, Guida E, Todaro F, Di Agostino S, et al
    Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    March 2017
  31. ZHAI Z, Liu W, Kaur M, Luo Y, et al
    NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma.
    Oncogene. 2017 Mar 6. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  32. YANG H, Kircher DA, Kim KH, Grossmann AH, et al
    Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
    Oncogene. 2017 Mar 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  33. SONG X, Hao J, Wang J, Guo C, et al
    The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling.
    Oncogene. 2017;36:1476-1486.
    PubMed     Text format     Abstract available


    February 2017
  34. LUO S, Li Y, Ma R, Liu J, et al
    Downregulation of PCK2 remodels tricarboxylic acid cycle in tumor-repopulating cells of melanoma.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    January 2017
  35. JEONG M, Lee EW, Seong D, Seo J, et al
    USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability.
    Oncogene. 2017;36:458-470.
    PubMed     Text format     Abstract available


  36. DOUDICAN NA, Orlow SJ
    Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
    Oncogene. 2017;36:423-428.
    PubMed     Text format     Abstract available


  37. BROWN K, Yang P, Salvador D, Kulikauskas R, et al
    WNT/beta-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  38. WORRALL C, Suleymanova N, Crudden C, Trocoli Drakensjo I, et al
    Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  39. DELYON J, Servy A, Laugier F, Andre J, et al
    PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  40. KIM HS, Jung M, Kang HN, Kim H, et al
    Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  41. RIVERSO M, Montagnani V, Stecca B
    KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.
    Oncogene. 2017 Jan 9. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  42. BIANCHI-SMIRAGLIA A, Bagati A, Fink EE, Moparthy S, et al
    Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.
    Oncogene. 2017;36:84-96.
    PubMed     Text format     Abstract available


    November 2016
  43. WANG Y, Ou Z, Sun Y, Yeh S, et al
    Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    October 2016
  44. FAIAO-FLORES F, Alves-Fernandes DK, Pennacchi PC, Sandri S, et al
    Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
    Oncogene. 2016 Oct 17. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    July 2016
  45. AGAESSE G, Barbollat-Boutrand L, Sulpice E, Bhajun R, et al
    A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion.
    Oncogene. 2016 Jul 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    June 2016
  46. JIANG CC, Croft A, Tseng HY, Guo ST, et al
    Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.
    Oncogene. 2016 Jun 27. doi: 10.1038/onc.2016.
    PubMed     Text format    


  47. RATNIKOV BI, Scott DA, Osterman AL, Smith JW, et al
    Metabolic rewiring in melanoma.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    May 2016
  48. DE DONATIS GM, Le Pape E, Pierron A, Cheli Y, et al
    NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.
    Oncogene. 2016;35:2813.
    PubMed     Text format    


    April 2016
  49. ZHANG P, Feng S, Liu G, Wang H, et al
    CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation.
    Oncogene. 2016 Apr 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    March 2016
  50. PENG C, Zeng W, Su J, Kuang Y, et al
    Cyclin-dependent kinase 2 (CDK2) is a key mediator for EGF-induced cell transformation mediated through the ELK4/c-Fos signaling pathway.
    Oncogene. 2016;35:1170-9.
    PubMed     Text format     Abstract available


    January 2016
  51. ASCHACHER T, Wolf B, Enzmann F, Kienzl P, et al
    LINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines.
    Oncogene. 2016;35:94-104.
    PubMed     Text format     Abstract available


    October 2015
  52. MUKHOPADHYAY P, Ferguson B, Muller HK, Handoko HY, et al
    Murine melanomas accelerated by a single UVR exposure carry photoproduct footprints but lack UV signature C>T mutations in critical genes.
    Oncogene. 2015 Oct 19. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  53. KALE S, Raja R, Thorat D, Soundararajan G, et al
    Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha9beta1 integrin.
    Oncogene. 2015;34:5408-10.
    PubMed     Text format    


  54. FELLI N, Errico MC, Pedini F, Petrini M, et al
    AP2alpha controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression.
    Oncogene. 2015 Oct 5. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    September 2015
  55. PEROTTI V, Baldassari P, Molla A, Vegetti C, et al
    NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
    Oncogene. 2015 Sep 21. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  56. DE DONATIS GM, Pape EL, Pierron A, Cheli Y, et al
    NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.
    Oncogene. 2015 Sep 14. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    August 2015
  57. KRUISWIJK F, Hasenfuss SC, Sivapatham R, Baar MP, et al
    Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling.
    Oncogene. 2015 Aug 17. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    July 2015
  58. MATHSYARAJA H, Thies K, Taffany DA, Deighan C, et al
    CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth.
    Oncogene. 2015;34:3651-61.
    PubMed     Text format     Abstract available


    June 2015
  59. FLASHNER-ABRAMSON E, Klein S, Mullin G, Shoshan E, et al
    Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.
    Oncogene. 2015 Jun 29. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  60. FEDORENKO IV, Abel EV, Koomen JM, Fang B, et al
    Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.
    Oncogene. 2015 Jun 15. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  61. KURIYAMA S, Yoshida M, Yano S, Aiba N, et al
    LPP inhibits collective cell migration during lung cancer dissemination.
    Oncogene. 2015 Jun 1. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    April 2015
  62. ZHAO T, Du H, Ding X, Walls K, et al
    Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal(-/-) mice.
    Oncogene. 2015;34:1938-48.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: